BRPI0515944A - processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carboni l)amino]fenóxi}n-metilpiridina-2-carboxamida - Google Patents

processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carboni l)amino]fenóxi}n-metilpiridina-2-carboxamida

Info

Publication number
BRPI0515944A
BRPI0515944A BRPI0515944-0A BRPI0515944A BRPI0515944A BR PI0515944 A BRPI0515944 A BR PI0515944A BR PI0515944 A BRPI0515944 A BR PI0515944A BR PI0515944 A BRPI0515944 A BR PI0515944A
Authority
BR
Brazil
Prior art keywords
amino
chloro
formula
methylpyridine
carboxamide
Prior art date
Application number
BRPI0515944-0A
Other languages
English (en)
Inventor
Michael Loegers
Reinhold Gehring
Oliver Kuhn
Mike Matthaeus
Klaus Mohrs
Matthias Mueller-Gliemann
Juergen Stiehl
Mathias Berwe
Jana Lenz
Werner Heilmann
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515944(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0515944A publication Critical patent/BRPI0515944A/pt
Publication of BRPI0515944B1 publication Critical patent/BRPI0515944B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Developing Agents For Electrophotography (AREA)

Abstract

"PROCESSO PARA A PREPARAçãO DE 4-{4-¢({¢4-CLORO-3-(TRIFLUOROMETIL)FENIL!AMINO!CARBONI L)AMINO!FENóXI!N-METILPIRIDINA-2-CARBOXAMIDA". A presente invenção refere-se a um processo para preparo de 4-{4-¢({¢4-cloro-3-(trifluorometil)fenil!amino}carbonil)amino!fenóxi}-N- metilpiridina-2-carboxamida e seu sal de tosilato. Fórmula I, a qual compreende, em uma primeira etapa, reação do composto da fórmula (V) com isocianato de 4-cloro-3-trifluorometilfenila em um solvente orgânico não-clorado, inerte com relação a isocianatos, através de inicialmente carregamento do composto da fórmula (V) a uma temperatura de 20<198>C a 60<198>C e mistura com isocianato de 4-cloro-3-trifluorometilfenila de um tal modo que a temperatura de reação não exceda 70<198>C para produzir o composto da fórmula (II) e, em uma segunda etapa, mistura do composto da fórmula (II) com ácido p-toluenossulfónico em um solvente polar a uma temperatura de reação de 40<198>C até a temperatura de refluxo do solvente usado.
BRPI0515944-0A 2004-09-29 2005-09-20 Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida BRPI0515944B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04023131 2004-09-29
EP04023131.8 2004-09-29
PCT/EP2005/010118 WO2006034796A1 (en) 2004-09-29 2005-09-20 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Publications (2)

Publication Number Publication Date
BRPI0515944A true BRPI0515944A (pt) 2008-08-12
BRPI0515944B1 BRPI0515944B1 (pt) 2021-11-09

Family

ID=35457568

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515944-0A BRPI0515944B1 (pt) 2004-09-29 2005-09-20 Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida

Country Status (34)

Country Link
US (1) US8124782B2 (pt)
EP (1) EP1797037B1 (pt)
JP (2) JP2008514657A (pt)
KR (1) KR101263032B1 (pt)
CN (1) CN101052619B (pt)
AR (1) AR053973A1 (pt)
AU (1) AU2005289099B2 (pt)
BR (1) BRPI0515944B1 (pt)
CA (1) CA2581835C (pt)
CU (1) CU23754B7 (pt)
CY (1) CY1116126T1 (pt)
DK (1) DK1797037T3 (pt)
DO (1) DOP2005000183A (pt)
EC (1) ECSP077357A (pt)
ES (1) ES2532377T3 (pt)
GT (1) GT200500269A (pt)
HN (1) HN2005000768A (pt)
HR (1) HRP20150295T1 (pt)
IL (1) IL182046A0 (pt)
MA (1) MA28883B1 (pt)
MY (1) MY149873A (pt)
NO (1) NO339647B1 (pt)
NZ (1) NZ554119A (pt)
PE (5) PE20060825A1 (pt)
PL (1) PL1797037T3 (pt)
PT (1) PT1797037E (pt)
SG (1) SG155997A1 (pt)
SI (1) SI1797037T1 (pt)
SV (1) SV2006002243A (pt)
TW (1) TWI382973B (pt)
UA (1) UA90691C2 (pt)
UY (1) UY29143A1 (pt)
WO (1) WO2006034796A1 (pt)
ZA (1) ZA200702511B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
ES2532377T3 (es) 2004-09-29 2015-03-26 Bayer Healthcare Llc Procedimiento de preparación de 4-{4-[({[4-[cloro-3-(trifluorometil)fenil]amino}carbonil) amino]fenoxi}N-metilpiridina-2-carboxamida
AU2005289100B2 (en) 2004-09-29 2011-11-03 Bayer Healthcare Llc Thermodynamically stable form of bay 43-9006 tosylate
DE602006017188D1 (de) 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
EP2195286A2 (en) 2007-09-10 2010-06-16 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
WO2009054004A2 (en) * 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
EP2231612A1 (en) * 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
WO2009111061A1 (en) * 2008-03-06 2009-09-11 Sicor Inc. Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CA2775296A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
CA2775229C (en) * 2009-09-24 2014-07-29 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2011058522A1 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
EP2528899B1 (en) 2010-01-29 2014-10-15 Ranbaxy Laboratories Limited Sorafenib dimethyl sulphoxide solvate
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
JP2013538840A (ja) 2010-10-01 2013-10-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−（２−アリールアミノ）アリールスルホンアミドを含有する組み合わせ
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) * 2012-09-19 2016-03-30 齐鲁制药有限公司 索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) * 2013-12-13 2015-06-17 江苏豪森药业股份有限公司 高纯度索拉非尼的制备方法
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) * 2014-12-01 2016-03-30 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) * 2017-10-26 2018-04-17 魏海霞 索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) * 2020-06-10 2021-12-10 杭州中美华东制药有限公司 索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) * 1988-05-27 1990-01-05 Konica Corp 非線形光学材料
JP2971291B2 (ja) * 1993-06-02 1999-11-02 田辺製薬株式会社 光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) * 1996-03-27 2007-01-10 ポーラ化成工業株式会社 新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) * 1996-03-28 1997-12-09 Ajinomoto Co Inc 新規キサントン誘導体
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
HU230863B1 (hu) * 1999-01-13 2018-10-29 Bayer Healthcare Llc Omega-karboxi-arilcsoporttal helyettesített difenil-karbamidok, mint raf-kináz inhibitorok
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
EP2305255B1 (en) 2001-12-03 2012-08-22 Bayer HealthCare LLC Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
AU2003255424A1 (en) * 2002-08-13 2004-03-03 Sandoz Ag A cefdinir intermediate
DE60316590T2 (de) * 2002-10-21 2008-06-19 Kirin Beer K.K. N-(2-CHLOR-4-((6,7-DIMETHOXY-4-CHINOLYL)OXYÜPHENYLü-N'-(5-METHYL-3-ISOXAZOLYL)HARNSTOFFSALZIN KRISTALLINER FORM
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
ES2532377T3 (es) 2004-09-29 2015-03-26 Bayer Healthcare Llc Procedimiento de preparación de 4-{4-[({[4-[cloro-3-(trifluorometil)fenil]amino}carbonil) amino]fenoxi}N-metilpiridina-2-carboxamida

Also Published As

Publication number Publication date
IL182046A0 (en) 2007-07-24
KR101263032B1 (ko) 2013-05-09
US8124782B2 (en) 2012-02-28
HK1113484A1 (en) 2008-10-03
MY149873A (en) 2013-10-31
JP2013067625A (ja) 2013-04-18
WO2006034796A1 (en) 2006-04-06
MA28883B1 (fr) 2007-09-03
PE20091585A1 (es) 2009-10-31
ZA200702511B (en) 2008-07-30
HN2005000768A (es) 2010-09-17
AU2005289099A1 (en) 2006-04-06
CN101052619B (zh) 2012-02-22
TWI382973B (zh) 2013-01-21
DK1797037T3 (en) 2015-03-30
EP1797037B1 (en) 2014-12-17
SG155997A1 (en) 2009-10-29
CA2581835A1 (en) 2006-04-06
PT1797037E (pt) 2015-03-17
UY29143A1 (es) 2006-04-28
CU23754B7 (es) 2012-01-31
CY1116126T1 (el) 2017-02-08
PE20091586A1 (es) 2009-10-31
DOP2005000183A (es) 2006-03-31
CU20070069A7 (es) 2010-11-27
PE20060825A1 (es) 2006-10-20
PL1797037T3 (pl) 2015-07-31
SV2006002243A (es) 2006-10-13
PE20091587A1 (es) 2009-11-05
JP2008514657A (ja) 2008-05-08
BRPI0515944B1 (pt) 2021-11-09
HRP20150295T1 (hr) 2015-05-22
US20080262236A1 (en) 2008-10-23
AR053973A1 (es) 2007-05-30
JP5583190B2 (ja) 2014-09-03
PE20091584A1 (es) 2009-10-28
AU2005289099B2 (en) 2012-07-19
CN101052619A (zh) 2007-10-10
SI1797037T1 (sl) 2015-06-30
NO339647B1 (no) 2017-01-16
KR20070058676A (ko) 2007-06-08
CA2581835C (en) 2012-12-18
ECSP077357A (es) 2007-04-26
EP1797037A1 (en) 2007-06-20
GT200500269A (es) 2006-05-11
TW200626551A (en) 2006-08-01
UA90691C2 (en) 2010-05-25
NZ554119A (en) 2010-07-30
ES2532377T3 (es) 2015-03-26
NO20072173L (no) 2007-06-14

Similar Documents

Publication Publication Date Title
CY1116126T1 (el) Διαδικασια για την παρασκευη 4-{4-[({[4-χλωρο-3-(τριφθορομεθυλ)φαινυλ]αμινο}καρβονυλ)αmινο]φαινοξυ}ν-μεθυλπυριδιν-2-καρβοξαμιδιου
BRPI0706947B8 (pt) método de preparação de uma composição de micropartícula
BR9507927A (pt) Processo para a preparação de bis-cianoacrilatos
DE60310554D1 (de) Verfahren zur herstellung von chinolinderivaten
MXPA05006907A (es) Compuestos diazoicos cationicos, composiciones que los contienen como colorante directo, procedimiento de coloracion de fibras queratinicas y dispositivo.
PT874862E (pt) Processo para a 6-o-alquilacao de derivados de eritromicina
BRPI0502822A (pt) processo para a preparação de isocianatos orgánicos apresentando grupos carbodiimida e/ou uretonimina lìquidos, estáveis ao armazenamento com baixo ìndice de cor
BR9812873B1 (pt) processo para preparar derivados de triazolinationa.
PE20070007A1 (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
TW200628514A (en) Unsaturated group-containing polyimide resin, photosensitive resin composition containing the same and cured resin thereof
BRPI0116227B8 (pt) processo para a preparação de imidazotriazinonas substituídas por sulfonamida
WO2006040527A8 (en) Process for making phenoxy benzamide compounds
ATE512134T1 (de) Verfahren zur herstellung von 5-benzyloxy-2-(4- benzyloxyphenyl)-3-methyl-1h-indol
BRPI0923337B8 (pt) processo para produzir composto de organolítio, processo para produzir composto aromático substituído e ligante
BR0315671A (pt) Processo para a preparação de um composto
BR112016011160B1 (pt) Procedimento de fabricação para obtenção de n-benzil-2- (2-nitro-1h-imidazol-1-ila) acetamida
BRPI0611001A2 (pt) processo para a preparação de ácidos tetracarboxílicos
BR0109927A (pt) Processo para preparar éteres de oxima
BRPI0408653A (pt) sìntese de ésteres de ácido 2-clorometil-6-metilbenzóico
WO1995002573A3 (en) New method for n-cyclopropylation of aromatic amines, as well as compounds and compositions obtained
Verardo et al. Study of the Reaction between Carbamoyl Azides of α‐N‐Protected Amino Acids and Hydrazine Monohydrate
AU2003232820A1 (en) USE OF Alpha-DIALDEHYDES IN THE PRESENCE OF AN AMMONIUM SALT OF A BRONSTED ACID FOR DYEING KERATIN FIBRES
Reisi et al. MEDIUM EFFECT STUDIES ON THE ACID DISSOCIATION CONSTANTS OF 4-MEO-4-H-1-ME-THIOXANTHONE
AGHCHEHLOU et al. ADHESION AND PROLIFERATION OF HORSE FIBROBLAST AND KERATINOCYTE CELLS IN FIBRIN GLUE
ESFAHANI et al. Alkali-silica reaction (ASR) in concrete (the effect of test type, cement type and admixtures of silica fume and superplasticizer)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO POR FUSAO DE: BAYER HEALTHCARE AG

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 213/81

Ipc: C07D 213/81 (2006.01), A61P 35/00 (2006.01)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 5089941-27.2025.4.02.5101/RJ ORIGEM: 5089941-27.2025.4.02.5101/RJ PROCESSO NO: 9A VARA FEDERAL DO RIO DE JANEIRO NULIDADE DE PATENTE DE INVENCAO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: ACCORD FARMACEUTICA LTDA REU(S): BAYER HEALTHCARE LLC E INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL